FamiCord AG
V3VN.DE operates in the healthcare sector, focusing on biotechnology and healthcare facilities and services.
Business. V3VN.DE is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models and is listed on the Xetra exchange. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data. Consequently, the company is described at the industry level without further operational breakdown.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
V3VN.DE is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm generates revenue through service-based models and is listed on the Xetra exchange. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data. Consequently, the company is described at the industry level without further operational breakdown.
The company's capital structure is characterized by a debt-to-equity ratio of 1.28, indicating a relatively high level of leverage. Despite having cash and equivalents of 16,823,000 EUR, the company's liquidity is assessed as medium, and its free cash flow is negative at -6,825,000 EUR, suggesting cash flow constraints. The company's return on equity is -0.8586, and its return on assets is -0.0795, both of which are negative and indicate poor profitability relative to its equity and asset base.
The company's profitability is weak, with an operating loss of 9,258,000 EUR and a net loss of 12,136,000 EUR. These figures are below the industry median for profitability metrics, indicating that the company is underperforming its peers in terms of generating profit. The company's gross profit of 29,352,000 EUR is also below the industry median, suggesting that it is not as efficient in converting revenue into profit as its competitors.
The company's revenue is concentrated in a single segment, as no additional segments are disclosed. The geographic exposure is not specified, but the company's operations are likely centered in its home market. The lack of segment and geographic diversification increases the company's exposure to market-specific risks.
The company's growth trajectory is uncertain, as there are no specific numeric deltas provided for the current or next fiscal year. The company's operating cash flow of 8,655,000 EUR is positive, but the free cash flow is negative, indicating that the company is not generating enough cash to fund its operations and capital expenditures. The company's capital expenditure of -3,199,000 EUR suggests that it is investing in its operations, but the negative free cash flow indicates that these investments are not being funded by operating cash flow.
The company's risk factors include medium liquidity risk and low dilution potential. The key flag of net cash being negative after subtracting total debt indicates that the company's cash position is not sufficient to cover its debt obligations. The company's dilution potential is low, suggesting that there is little risk of share dilution in the near term.
Recent events include analyst estimates that suggest a mean price target of 7.50 EUR, with a mean recommendation of 3.00, indicating a hold rating. There are no strong buy or buy recommendations, and only one hold recommendation, suggesting that analysts are cautious about the company's prospects.
- The company has a high debt-to-equity ratio of 1.28, indicating a leveraged capital structure.
- The company's profitability is weak, with a negative return on equity and return on assets.
- The company's free cash flow is negative, indicating cash flow constraints.
- The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
- The company's liquidity risk is medium, and its dilution potential is low.
- margin_outlook_rationale: The company's margin outlook is negative due to its weak profitability and high operating costs.
- rd_outlook_rationale: The company's R&D outlook is uncertain, as there is no specific information provided on R&D expenditures or projects.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- V3VN.DE Market data — financials · 2026-05-29
- FamiCord AG Market data — analyst estimates · 2026-05-29